VRTX Collar Strategy
VRTX (Vertex Pharmaceuticals Incorporated), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Vertex Pharmaceuticals Incorporated is a leading biotechnology firm primarily focused on the discovery, advancement, and marketing of innovative treatments, particularly for cystic fibrosis (CF). The company offers a range of approved medications for CF patients, including SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which target specific mutations within the cystic fibrosis transmembrane conductance regulator gene. Additionally, they provide TRIKAFTA for individuals with CF aged six years and older who possess at least one F508del mutation. Beyond its established CF therapies, Vertex maintains a robust and diverse clinical pipeline. This includes VX-864, currently in Phase 2 for alpha-1 antitrypsin (AAT) deficiency; VX-147, also in Phase 2, addressing APOL1-mediated focal segmental glomerulosclerosis (FSGS) and other serious kidney conditions; VX-880, a potential treatment for Type 1 Diabetes undergoing Phase 1/2 trials; VX-548, a NaV1.8 inhibitor in Phase 2 for various forms of acute, neuropathic, and musculoskeletal pain; and CTX001, which is in Phase 3 development for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The company distributes its pharmaceutical products through specialty pharmacies and distributors across the United States, while international sales are facilitated via a network of specialty distributors, retail chains, hospitals, and clinics.
VRTX (Vertex Pharmaceuticals Incorporated) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $124.70B, a trailing P/E of 28.78, a beta of 0.31 versus the broader market, a 52-week range of 362.5-507.92, average daily share volume of 1.4M, a public-listing history dating back to 1991, approximately 6K full-time employees. These structural characteristics shape how VRTX stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.31 indicates VRTX has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a collar on VRTX?
A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot.
Current VRTX snapshot
As of June 30, 2026, spot at $495.96, ATM IV 28.94%, IV rank 32.11%, expected move 8.30%. The collar on VRTX below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 31-day expiry.
Why this collar structure on VRTX specifically: IV regime affects collar pricing on both sides; mid-range VRTX IV at 28.94% typically pushes the short call premium to roughly offset the long put cost, with a market-implied 1-standard-deviation move of approximately 8.30% (roughly $41.14 on the underlying). The 31-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated VRTX expiries trade a higher absolute premium for lower per-day decay. Position sizing on VRTX should anchor to the underlying notional of $495.96 per share and to the trader's directional view on VRTX stock.
VRTX collar setup
The VRTX collar below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With VRTX near $495.96, the first option leg uses a $520.00 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed VRTX chain at a 31-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 VRTX shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 100 shares | Stock | $495.96 | long |
| Sell 1 | Call | $520.00 | $7.30 |
| Buy 1 | Put | $470.00 | $5.55 |
VRTX collar risk and reward
- Net Premium / Debit
- -$49,421.00
- Max Profit (per contract)
- $2,579.00
- Max Loss (per contract)
- -$2,421.00
- Breakeven(s)
- $494.21
- Risk / Reward Ratio
- 1.065
Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium.
VRTX collar payoff curve
Modeled P&L at expiration across a range of underlying prices for the collar on VRTX. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
| Underlying Price | % From Spot | P&L at Expiration |
|---|---|---|
| $0.01 | -100.0% | -$2,421.00 |
| $109.67 | -77.9% | -$2,421.00 |
| $219.33 | -55.8% | -$2,421.00 |
| $328.99 | -33.7% | -$2,421.00 |
| $438.64 | -11.6% | -$2,421.00 |
| $548.30 | +10.6% | +$2,579.00 |
| $657.96 | +32.7% | +$2,579.00 |
| $767.62 | +54.8% | +$2,579.00 |
| $877.28 | +76.9% | +$2,579.00 |
| $986.94 | +99.0% | +$2,579.00 |
When traders use collar on VRTX
Collars on VRTX hedge an existing long VRTX stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
VRTX thesis for this collar
The market-implied 1-standard-deviation range for VRTX extends from approximately $454.82 on the downside to $537.10 on the upside. A VRTX collar hedges an existing long VRTX position with a protective put while financing the put cost via a short call; when the premiums roughly offset, the collar acts as a near-zero-cost insurance band around the current spot. Current VRTX IV rank near 32.11% is mid-range against its 1-year distribution, so the IV signal is neutral; the collar thesis on VRTX should anchor more to the directional view and the expected-move geometry. As a Healthcare name, VRTX options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to VRTX-specific events.
VRTX collar positions are structurally neutral (protective); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. VRTX positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move VRTX alongside the broader basket even when VRTX-specific fundamentals are unchanged. Always rebuild the position from current VRTX chain quotes before placing a trade.
Frequently asked questions
- What is a collar on VRTX?
- A collar on VRTX is the collar strategy applied to VRTX (stock). The strategy is structurally neutral (protective): A collar pairs long stock with a protective out-of-the-money put financed by a short out-of-the-money call, capping both tails of the position around the current spot. With VRTX stock trading near $495.96, the strikes shown on this page are snapped to the nearest listed VRTX chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are VRTX collar max profit and max loss calculated?
- Max profit roughly equals short-call strike minus cost basis plus net premium; max loss roughly equals cost basis minus long-put strike minus net premium. Breakeven shifts by the net premium. For the VRTX collar priced from the end-of-day chain at a 30-day expiry (ATM IV 28.94%), the computed maximum profit is $2,579.00 per contract and the computed maximum loss is -$2,421.00 per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a VRTX collar?
- The breakeven for the VRTX collar priced on this page is roughly $494.21 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current VRTX market-implied 1-standard-deviation expected move is approximately 8.30%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a collar on VRTX?
- Collars on VRTX hedge an existing long VRTX stock position; the long put sets a floor while the short call finances it, often run as a near-zero-cost hedge during expected volatility windows.
- How does current VRTX implied volatility affect this collar?
- VRTX ATM IV is at 28.94% with IV rank near 32.11%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.